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doi:10.1Objective: The study objective was to evaluate the roles of mitochondrial DNA alterations in esophageal squa-
mous cell carcinoma, with emphasis on the changes in the copy number and D310 variants of mitochondrial DNA.
Methods: Paired samples microdissected from esophageal muscles, noncancerous esophageal mucosa, cancer-
ous esophageal squamous cell carcinoma nests, and metastatic lymph nodes of 72 patients with esophageal squa-
mous cell carcinoma were subjected to DNA extraction. The copy number and D310 variants of mitochondrial
DNA were determined by quantitative real-time polymerase chain reaction and direct sequencing, respectively.
Results: Fifty-six patients (77.8%) with somatic D310 mutations had lower survival probability (P¼ .027). From
noncancerous esophageal mucosa to cancerous esophageal squamous cell carcinoma nests and metastatic lymph no-
des, the D310 variants were decreased from 2.2 to 1.7 and 1.5, respectively, with a trend to homoplasmy (P¼ .0009).
Concurrently, the mitochondrial DNA copy number was increased from 0.159 to 0.192 and 0.206, respectively, (P¼
.024), especially in cigarette smokers (P¼ .014) and heavy wine drinkers (P¼ .005). Notably, a decrease in D310
variants (1.5,P<.001) and an increase in the incidence of the homoplasmic D310 pattern (P¼ .005) were observed in
the matched esophageal muscle tissues. Among the 56 esophageal squamous cell carcinoma cancer nests with so-
matic D310 mutations, 51 (91.1%) had D310 variants in association with their corresponding noncancerous esoph-
ageal mucosa, including 36 (64.3%) fully related and 15 (26.8%) partially related pairs.
Conclusion: We demonstrated that somatic D310 mutations and increase in the copy number of mitochondrial
DNA are of clinical importance in esophageal squamous cell carcinoma. We also propose a model of DNA in-
stability and clonal expansion during the carcinogenesis and progression of esophageal squamous cell carcinoma
from the viewpoint of mitochondrial DNA transmission. (J Thorac Cardiovasc Surg 2010;139:189-97)Supplemental material is available online.
Esophageal squamous cell carcinoma (ESCC) is an aggres-
sive malignant neoplasm in patients in Asian countries.
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Sdecades in Taiwan, the survival outcome remains dismal.1-3
Several clinical and molecular prognostic factors have been
investigated in patients with ESCC.1-3 However, most studies
are concerned with the roles of nuclear DNA (nDNA)
mutations, and less attention has been paid to mitochondrial
DNA (mtDNA) alterations. Thus, appraisal of the role of
mtDNA alterations in the pathophysiology of ESCC is of
great clinical importance.
Each human cell contains several hundred to 1000 mito-
chondria, and each mitochondrion has 2 to 10 copies of
mtDNA. In contrast with the heterozygotic characteristics
of nDNA inherited from parents, mtDNA is transmitted
through the maternal lineage. In addition, the majority of
mtDNA copies in the cells of post-mitotic tissues of an indi-
vidual are identical at birth with a pattern termed ‘‘homo-
plasmy.’’4,5 Human mtDNA accumulates damages and
mutations at a rate approximately 17 times greater than
does the nDNA.5,6 When the mutated mtDNA molecules co-
exist with the wild-type mtDNA, the homoplasmy is disrup-
ted and shifted to the so-called heteroplasmy.4
Human mtDNA is a 16,569 base-pair, double-stranded,
closed-circular DNA molecule that encodes 13 polypeptides,
2 rRNAs, and a set of 22 tRNAs required for protein synthesis
in mitochondria. The displacement loop located at nucleotide
position (np) 16024–576 with 1.1 kb in size is a noncodingrdiovascular Surgery c Volume 139, Number 1 189
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ANOVA ¼ analysis of variance
ESCC ¼ esophageal squamous cell carcinoma
mtDNA ¼ mitochondrial DNA
nDNA ¼ nuclear DNA
np ¼ nucleotide position
PCR ¼ polymerase chain reactionregion essential for the replication and transcription of
mtDNA.7 The displacement loop has been discovered as
a hot spot for mutation in several human cancers, especially
in the D310 region.8
There is a polycytidine tract consisting of repeated mono-
cytidine between np 303 and np 316 with a thymidine inter-
posed at np 310 (ie, -C303CCCCCC-T310-CCCCCC316-).
Generally, the cytidine number before thymidine is 7 (C-7,
wild type), but 6, 8, 9, 10, and 11 (C-6, C-8, C-9, C10, C-
11 variants) have also been reported in different individuals
(http://www.mitomap.org).9 Such variations among human
populations are referred to as D310 polymorphisms or
D310 variants. Somatic D310 mutation (ie, altered D310
variants between matched cancerous and noncancerous
counterparts) was recently found in several human cancers,
including head and neck, lung, gastric, breast, and prostate
cancers.10,11 However, little is known about such mutations
in ESCC.12,13 Because of the regulatory role of the displace-
ment loop in mtDNA replication, it is important to determine
whether such D310 mutations are associated with quantita-
tive changes in mtDNA copy number. Although changes
in mtDNA copy number have been reported in several
human cancers, as an increase in head and neck cancers14
or a decrease in advanced gastric cancer, breast cancer,
and hepatocellular carcinomas,11,15-17 their clinical signifi-
cance remains unclear.
In this study, we investigated the mtDNA alterations,
mainly focused on D310 mutations and change in mtDNA
copy number, and their association with the clinical outcomes
of ESCC. Possible factors, including demographic data, his-
tory of cigarette smoking or alcohol drinking, and tumor char-
acteristics, which might be related to mtDNA alterations, were
also evaluated. Finally, we propose a model to explain the role
of mtDNA alterations in the pathophysiology of ESCC.
MATERIALS AND METHODS
Patient Selection
Patients with resectable ESCC and without obvious distant organ metas-
tasis on preoperative assessments who received complete surgical resection
(including transthoracic subtotal esophagectomy, gastric tube reconstruc-
tion with esophagogastric anastomosis in the neck, and radical lymph
node dissection) as their primary treatment modality at Taipei Veterans
General Hospital were enrolled between 2000 and 2003. None of the
patients received preoperative neoadjuvant chemotherapy or radiotherapy.
The patients’ pathologic data (TNM status according to the American Joint0 The Journal of Thoracic and Cardiovascular SurgCommittee on Cancer18) and clinical data (eg, smoking status, alcohol con-
sumption, and overall survival period) were recorded in detail for systemic
analysis. All patients were followed up until December 2006, and the pre-
liminary results have been reported.3 The patients’ clinical data and patho-
logic slides were subject to review, and a total of 72 ESCC cases were
recruited for analysis in this study. Institutional review board approval
from Taipei Veterans General Hospital was obtained to conduct this retro-
spective study (VGHIRB No: 95-11-15A).
Tissue Collection and DNA Extraction
With the assistance of anexperienced pathologist, representative tumor foci
without necrosis and lymphocyte infiltration on pathologic slides were located,
and thin slices approximately 5 mm in thickness from corresponding paraffin-
embedded tissue blocks were prepared for laser microdissection. Under the
guidance of the hematoxylin-eosin Y stain, paired pathologically normal non-
cancerous esophageal mucosa and underlying esophageal muscle tissues and
the cancerous ESCC nests from each patient were microdissected using a laser
beam under a light microscope (Figure E1). Among the 72 patients with
ESCC, 44 had lymph node metastasis, and pathologic blocks containing the
metastatic lymph nodes of 37 patients were retrieved adequately for laser mi-
crodissection. The tissue samples were stored in 0.5 mL Eppendorf vials and
mixed with 60 mL QuickExtract DNA extraction solution (Epicenter, Madi-
son, Wis) to extract total cellular DNA at 65C for 3 hours.19 The quality of
the extracted DNA was verified by the ratio between the absorbance at 260
and 280 nm, and the existence of a DNA band polymerase chain reaction
(PCR) amplified from 18S rRNA gene after electrophoresis and ethidium bro-
mide staining. The DNA sample was kept at20C until use.
Sequencing of the D310 Region
The D310 region was PCR amplified from the extracted DNA and then
subjected to direct sequencing. Each 50-mL PCR reaction contained 25 mL
of AmpliTaq Gold PCR Master Mix (Applied Biosystems, Foster City,
Calif), 22 mL of PCR-grade H2O, 1 mL of each primer (H76-1: 5
0-CACGC
GATAGCATTGCGA-30 and L335: 50-TAAGTGCTGTGGCCAGAAGC -30),
and 1 mL of sample DNA.20 The PCR conditions were set at 95C for 5 min-
utes followed by 40 cycles of amplification at 95C for 15 seconds, 58C for
15 seconds, and 72C for 30 seconds, and the final extension at 72C for 7
minutes. PCR products were subject to electrophoresis on a 3% agarose
gel to separate the DNA bands and visualized by ultraviolet light illumination
after ethidium bromide staining. The DNA band of interest was then cut out
of the gel and subject to direct sequencing. The results were compared in
pairs with reference to the human mitochondrial genome database (http://
www.mitomap.org).9
Determination of Mitochondrial DNACopy Number
The mtDNA copy number was determined as mtDNA/nDNA ratio by
quantitative real-time PCR. For each 10-mL reaction, 1 mL of unknown
DNA was amplified in a capillary containing 0.25 mL of each primer
(20 mM), 1.2 mL 3 mmol/L MgCl2, 1 mL LightCycler SYBR Green mixed
reagent (Roche Applied Science, Mannheim, Germany), and 6.3 mL PCR-
grade H2O. Also amplified were DNA samples from 143B cells (1.25 ng/
mL) and PCR-grade H2O as the positive and negative controls, respectively.
The PCR was performed with hot start at 95C for 10 minutes followed by
40 cycles of 95C for 20 seconds, 62C for 20 seconds, and 72C for 20 sec-
onds. The sequences of primers used to amplify mtDNA (ND1 region) were
mtF3212, 50-CACCCAAGAA CAGGGTTTGT-30 and mtR3319, 50-
TGGCCATGGGATTGTTGTTAA-30. The sequences of primers used to
amplify nDNA (18S rRNA gene) were 18S1546F 50-TAGAGG GA
CAAGTGGCGTTC-30 and 18S1650R 50-CGCTGAGCCAGTCAGTGT-
30.21 Standard curves representing the quantities of both mtDNA and
nDNA related to replication threshold cycles were established by using
DNA from 143B osteosarcoma cells (R2 ¼ 0.9973 for mtDNA and R2 ¼
.9973 for nDNA) as previously reported.21 The mtDNA copy number ofery c January 2010
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mtDNA copy numbers of clinical samples were then determined accord-
ingly. Each analysis was done in duplicate, and the value of the mean
was used for data presentation.
Statistics
All statistical analyses in this study were performed using the Statistical
Package for the Social Sciences, 12.0 (SPSS Inc, Chicago, Ill) and Statistics
Analysis System 9.1 (SAS Institute Inc, Cary, NC). The continuous vari-
ables between groups were compared using the Student t test/Mann–Whit-
ney test, analysis of variance (ANOVA)/Kruskal–Wallis test, or paired t test
when appropriate. Categoric variables between groups were compared us-
ing the chi-square test, Fisher’s exact test, or Cochrane–Armitage test for
trend when appropriate. Survival probability was calculated and presented
by the Kaplan–Meier plot. The log-rank test was used to compare different
survival probabilities among different levels within each categoric variable.
Possible prognostic factors associated with survival probability at a signifi-
cance level of .20 or less were considered in a multivariable Cox’s propor-
tional hazard regression analysis.RESULTS
Clinical Data
Between January 2000 and December 2003, 72 patients
with ESCC (62 men, 86.1%) with a mean age of 60.1 years
were eligible for analysis. The demographic data are summa-
rized in Table 1. Fifty-six patients (77.8%) smoked cigarettes
with a mean smoking index (packages smoked per day times
years of smoking; pack-year) of 35.8  22.2, and 57 patients
(79.2%) drank alcohol with a mean alcohol consumption
index (bottles consumed per day times years of drinking; bot-
tle-year) of 23.6  18.5. On the basis of the American Joint
Committee on Cancer staging system, 6 patients (8.3%)
were in stage I, 21 patients (29.2%) were in stage II, 18 pa-
tients (25.0%) were in stage III, and 27 -patients (37.5%)
were in stage IV of nonregional lymph node metastasis.
The overall mean and median survival periods were 30.7
months (95% confidence interval, 25.0–36.3) and 24.2
months (95% confidence interval, 16.8–31.6), respectively.
Eleven patients (15.3%) underwent incomplete R1 resection
because of the presence of microscopically atypical cells (3
dysplasia, 4 carcinoma in situ, 4 invasive carcinoma) in
the proximal resection margin of the cervical esophagus.
Although all the distal resection margins over the gastric
cardia were free of carcinoma invasion, 9 patients (12.5%)
were found to have ESCC cancer nests in the gastric cardia.E
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Tissues of Patients With Esophageal Squamous Cell
Carcinoma
Distributions of the major D310 variants of the examined tis-
sues are summarized in Table 2. By taking the noncancerous
esophageal mucosa of patient A01 as an example, 3 kinds of
D310 variants were found (C-8, C-9, and C-10; heteroplasmic),
and C-8 was the major variant (Table E1). Among the major
D310 variants in the examined tissues, C-8 was the most com-
mon followed by C-7. C-8 as the major variant was noted inThe Journal of Thoracic and Ca56.9% (n ¼ 41) of 72 muscle tissues, 38.9% (n ¼ 28) of 72
noncancerous mucosa, 45.8% (n ¼ 33) of 72 ESCC nests,
and 48.6% (n ¼ 18) of 37 metastatic lymph nodes.
D310 Sequence Variations in Noncancerous
Esophageal Mucosa and Paired Cancerous
Esophageal Squamous Cell Carcinoma Nests
Changes in D310 variants between the noncancerous
esophageal mucosa and the paired cancerous ESCC nests
in each patient were compared, and 5 types of alterations
were classified, including 16 patients (22.2%) with type I
(homoplasmic to the same homoplasmic variant), 8 patients
(11.1%) with type II (homoplasmic to heteroplasmic),
23 patients (31.9%) with type III (heteroplasmic to hetero-
plasmic), 23 patients (31.9%) with type IV (heteroplasmic
to homoplasmic), and 2 patients (1.5%) with type V (one
homoplasmic variant to another homoplasmic variant)
alterations (Tables 3 and E1; Figure E2). We defined type
II, III, IV, and V alterations as D310 mutations (n ¼ 56,
77.8%) resulting from any shift in the proportions of
D310 variants between noncancerous esophageal mucosa
and paired cancerous ESCC nests, and type I alteration
(n ¼ 16, 22.2%) was regarded as no mutation. By using
patient A01 as an example (Table E1), C-8 (major), C-9,
and C-10 variants coexisting in the noncancerous esopha-
geal mucosa were changed to C-9 (major), C-8, and C-10
variants coexisting in the paired cancerous ESCC nest.
We thus defined this patient as having type III D310 alter-
ation with D310 mutation.
Relationship Between D310 Variants in Cancerous
Esophageal Squamous Cell Carcinoma Nests and
Matched Noncancerous Esophageal Mucosa
The relationship between D310 variants in the cancerous
ESCC nests and the corresponding noncancerous esophageal
mucosa of each patient was analyzed and grouped as follows:
(1) fully related (n¼ 52, 72.2%): All the D310 variants of the
cancerous ESCC nests already existed in the paired noncan-
cerous esophageal mucosa (eg, patient A01), including 16
(22.2%) without D310 mutations and 36 (50%) with D310
mutations; (2) partially related (n ¼ 15, 20.8%): Some but
not all of the D310 variants of the cancerous ESCC nests ex-
isted in the paired noncancerous esophageal mucosa (eg, pa-
tient B08), and all of them harbored D310 mutations; (3) not
related (n ¼ 5, 6.9%): None of the D310 variants of the can-
cerous ESCC nests existed in the paired noncancerous esoph-
ageal mucosa (eg, patient E12), and all of them harbored
D310 mutations (Tables 3 and E1).
Prognostic Roles of Somatic D310 Mutation and
Other Factors
There were 56 patients (77.8%) with ESCC harboring
D310 mutations with poorer prognosis (P ¼ .027, log-rank
test) (Figure 1, A; Table 1). Other clinical factors, includingrdiovascular Surgery c Volume 139, Number 1 191
TABLE 1. Demographic data and possible prognostic factors affecting survival probability in patients with esophageal squamous cell carcinoma
Multivariable
Demographic
data/prognostic factors (%)
Overall survival
Mean (95% CI) (mo)
Univariable
P (log-rank) Hazard ratio 95% CI P (Cox regression)
D310 mutation .027 .002
Yes (n ¼ 56) (77.8) 26.9 (20.7–33.0) 1.000
No (n ¼ 16) (22.2) 40.9 (30.3–51.5) 0.258 0.109–0.614
Gender .615
Male (n ¼ 62) (86.1) 30.0 (23.8–36.3)
Female (n ¼ 10) (13.9) 34.9 (23.0–46.8)
Presenting symptoms
Difficulty in swallowing .017 .329
Yes (n ¼ 58) (80.6) 25.9 (20.5–31.3)
No (n ¼ 14) (19.4) 46.4 (33.4–59.5)
Body weight loss .829
Yes (n ¼ 20) (27.8) 29.4 (19.3–39.4)
No (n ¼ 52) (72.2) 30.3 (23.8–36.7)
Special habit
Cigarette smoking .258
Yes (n ¼ 56) (77.8) 28.7 (22.4–35.0)
No (n ¼ 16) (22.2) 36.0 (24.8–47.1)
Alcohol drinking .5773
Yes (n ¼ 57) (79.2) 29.7 (23.4–36.1)
No (n ¼ 15) (20.8) 31.4 (21.4–41.5)
Pathologic findings
Esophageal resection margin invasion* .073 .081
Yes (n ¼ 11) (15.3) 18.7 (9.67–27.7)
No (n ¼ 61) (84.7) 32.5 (26.3–38.7)
Gastric cardia invasion .001 .383
Yes (n ¼ 9) (12.5) 10.1 (3.5–16.7)
No (n ¼ 63) (87.5) 33.2 (27.3–39.2)
T-status (depth of tumor invasion) .005 .004
T1 (n ¼ 7) (9.7) 45.0 (26.9–63.1) T1 vs T4 0.232 0.060–0.896 .034
T2 (n ¼ 13) (18.1) 38.4 (27.4–49.4) T2 vs T4 0.235 0.092–0.599 .002
T3 (n ¼ 29) (40.3) 30.7 (23.4–38.0) T3 vs T4 0.314 0.149–0.658 .002
T4 (n ¼ 23) (31.9) 14.5 (9.3–19.6) T4 vs T4 1.000
N-status <.001 .007
N() (n ¼ 28) (38.9) 44.0 (35.2–52.7) 0.410 0.197–0.855
N (þ) (n ¼ 44) (61.1) 21.5 (15.9–27.2) 1.000
M-status .117 .689
M0 (n ¼ 45) (62.5) 35.2 (28.0–42.5)
M1a (n ¼ 12) (16.7) 22.4 (12.5–32.3)
M1b (n ¼ 15) (20.8) 22.9 (11.8–34.0)
Cancer stage (AJCC) .043 .363
I (n ¼ 6) (8.3) 48.6 (28.4–68.9)
II (n ¼ 21) (29.2) 38.0 (28.8–47.2)
III (n ¼ 18) (25.0) 22.2 (14.1–30.3)
IV (n ¼ 27) (37.5) 22.4 (14.9–29.8)
Postoperative adjuvant therapy
Radiotherapy .9395
Yes (n ¼ 22) (30.6) 29.4 (20.5–38.2)
No (n ¼ 50) (69.4) 30.5 (23.6–37.3)
Chemotherapy .2378
Yes (n ¼ 26) (36.1) 25.3 (18.5–32.1)
No (n ¼ 46) (63.9) 33.3 (25.6–40.9)
AJCC, American Joint Committee on Cancer; CI, confidence interval. *Cervical esophageal resection margins invasion indicates R1 resection, that is, atypical cells (3 dysplasia, 4
carcinoma in situ, 4 invasive carcinoma) were found in the resection margin during microscopic examination.
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TABLE 2. Distribution of D310 patterns and mtDNA copy numbers among the esophageal muscular tissues, noncancerous esophageal mucosa,
cancerous esophageal squamous cell carcinoma nests, and metastatic lymph nodes in 72 patients with esophageal squamous cell carcinoma
Reference tissues Target tissues
Esophageal
muscular tissues
Noncancerous
esophageal mucosa
Cancerous
ESCC nests
Metastatic
lymph nodes
n ¼ 72 (100) n ¼ 72 (100) n ¼ 72 (100) n ¼ 37 (100) P valuek P value{ P value#
D310 parameters
Pattern of D310 distribution
Homoplasmic (%) 43 (59.7) 26 (36.1) 41 (56.9) 25 (67.6) .005* .012* <.001z
Heteroplasmic (%) 29 (40.3) 46 (63.9) 31 (43.1) 12 (32.4)
No. of D310 variants
Mean  SD 1.5  0.8 2.2  1.0 1.7  1.0 1.5  0.8 <.001y .002y .001x
Median 1.0 2.0 1.0 1.0
Major D310 variant
C-7 (%) 25 (34.7) 29 (40.3) 27 (37.5) 13 (35.1) .491* .732* .589z
Non C-7 (%) 47 (65.3) 43 (59.7) 45 (62.5) 24 (64.9)
C-8 (%) 41 (56.9) 28 (38.9) 33 (45.8) 18 (48.6)
C-9 (%) 6 (8.3) 11 (15.3) 9 (12.5) 5 (13.5)
Others (%) 0 (0) 4 (5.6) 3 (4.2) 1 (2.7)
mtDNA copy no.
Mean  SD ND 0.159  0.056 0.192  0.111 0.206  0.113 ND .004y .024x
ESCC, Esophageal squamous cell carcinoma; SD, standard deviation; ND, not determined. *Chi-square test. yPaired t test. zCochrane–Armitage test for trend. xANOVA.
kCompared between matched esophageal muscular tissues and noncancerous esophageal mucosa. {Compared between matched noncancerous esophageal mucosa and cancerous
ESCC nests. #Compared among noncancerous esophageal mucosa, cancerous ESCC nests, and metastatic lymph nodes.
Lin et al Evolving Technology/Basic Scienceadvanced T status (P ¼ .005), positive lymph node metasta-
sis (P<.001), late cancer stage (P¼ .043), gastric cardia in-
vasion (P ¼ .001), invasion of the cervical esophageal
resection margins (P ¼ .073), and symptoms of swallowing
difficulty (P ¼ .017), were associated with shorter survival.
After conducting a Cox’s regression with stepwise analysis,
we found that D310 mutation (P ¼ .002), advanced T status
(P ¼ .004), and positive lymph node metastasis (P ¼ .007)
were independent risk factors related to worse outcomes
(Table 1). We found that patients with a higher degree of
D310 heteroplasmy (ie,>2 D310 variants) in the noncancer-
ous mucosa had a lower survival probability than did pa-
tients with a lower degree of D310 heteroplasmy (ie, 2
D310 variants) (P ¼ .005; Figure 1, B).E
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DNA Copy Numbers in Tissues of Patients With
Esophageal Squamous Cell Carcinoma
On average, each noncancerous esophageal mucosa har-
bored 2.2 kinds of D310 variants, each cancerous ESCC
nest harbored 1.7 kind of D310 variants, and each metastatic
lymph node harbored 1.5 kinds of D310 variants. There was
a stepwise decrease of D310 variants when ESCC pro-
gressed (P ¼ .001, ANOVA) and an increase in the inci-
dence of homoplasmic D310 pattern from noncancerous
esophageal mucosa (26/72, 36.1%) to cancerous ESCC
nests (41/72, 56.9%) and to metastatic lymph nodes (25/
37, 67.6%) (P ¼ .0009, Cochrane-Armitage test for trend)
(Table 2). The mean mtDNA copy number showed a step-
wise increase from the noncancerous esophageal mucosaThe Journal of Thoracic and Ca(0.159, n ¼ 72) to the cancerous ESCC nests (0.192, n ¼
72) (P¼ .004, paired t test) and then to the metastatic lymph
nodes (0.206, n ¼ 37) (P¼ .024, ANOVA) (Table 2) during
ESCC progression. In the pathologically normal tissues, the
kinds of D310 variants in the esophageal muscle (1.5) were
significantly less than those in paired noncancerous esopha-
geal mucosa (2.2) (P< .001, paired t test), with a higher
incidence of heteroplasmic pattern in the noncancerous
esophageal mucosa (P ¼ .005, c2 test) (Table 2).
Factors Related to Somatic D310 Mutation and
Mitochondrial DNA Copy Number Alteration
The possible contributory factors for somatic D310 muta-
tions are old age (P ¼ .015), heteroplasmy with multiple
D310 variants (P< .001), and major D310 variants other
than C-7 in noncancerous esophageal mucosa (P< .001)
(Table 4). To compare the changes of mtDNA copy number,
we defined the mtDNA copy ratio as the mtDNA copy num-
ber of the cancerous ESCC nest over the paired noncancer-
ous esophageal mucosa in each patient. Male patients
(P ¼ .012), cigarette smokers (P ¼ .014), alcohol drinkers
(P ¼ .005), and presence of the heteroplasmic D310 pattern
(P ¼ .015) and major variants other than C-7 (P ¼ .014) in
the noncancerous esophageal mucosa are associated with an
elevated mtDNA copy ratio (Table 4).
Quantitative Changes of Mitochondrial DNA Copy
Number When Harboring D310 Mutation
Among the 56 patients with somatic D310 mutations, 23
(41.1%) had type IV alteration (heteroplasmic tordiovascular Surgery c Volume 139, Number 1 193
TABLE 3. Differences of mtDNA copy ratios according to types of
D310 alteration and D310 clonal relationships
Classification Case No. (%)z
mtDNA
copy ratio P value
Without somatic D310
mutation (n ¼ 16)
16 (22.2) 1.09  0.41 .319y
Type of D310 alteration
I (homoplasmic to
homoplasmic)
16 (22.2) 1.09  0.41
Clonal relationship
Fully related 16 (22.2) 1.09  0.41
Partially related ND ND
Not related ND ND
With somatic D310
mutation (n ¼ 56)
56 (77.8) 1.28  0.72 .008y
Type of D310 alteration
II (homoplasmic to
heteroplasmic)
8 (11.1) 0.91  0.31 .048*
III (heteroplasmic to
heteroplasmic)
23 (31.9) 1.21  0.69
IV (heteroplasmic to
homoplasmic)
23 (31.9) 1.50  0.80
V (A homoplasmic to
B homoplasmic)
2 (1.5) 1.12  0.43
Clonal relationship
Fully related 36 (50) 1.35  0.68 .047*
Partially related 15 (20.8) 1.02  0.67
Not related 5 (6.9) 1.52  1.05
ND, Not determined; mtDNA copy ratio, mtDNA copy number of cancerous ESCC
nest/paired noncancerous esophageal mucosa. *ANOVA/Kruskall–Wallis. yPaired t
test (changes of the mtDNA copy number between the cancerous ESCC nest and
the paired noncancerous mucosa). zOverall percentage.
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(69.2%) had D310 variants in the ESCC cancerous nests fully
related to their noncancerous esophageal mucosa (Table 3).
Those with type IV alteration had a higher mtDNA copy ratio
than did those with types II, III, and V alterations (P¼ .048).
Moreover, patients with D310 variants in the cancerous
ESCC nests fully related to their paired noncancerous esoph-
ageal mucosa also had a higher mtDNA copy ratio compared
with those who harbored only partially related D310 variants
(P ¼ .047) (Table 3).
DISCUSSION
Somatic D310 mutations and their clinical significance in
human cancers have been recognized in the past de-
cade,10,11,15-17 especially in head and neck cancers.22 In re-
cent years, somatic D310 mutations have been detected in
ESCC.12,13 We demonstrated in this study that somatic
D310 mutation is an independent prognostic factor in pa-
tients with ESCC (Table 1). Heteroplasmic D310 variants
and major variants other than C-7 in the noncancerous
esophageal mucosa are associated with somatic D310 muta-
tions (Table 4). Previous studies of human lung cancers
showed that somatic D310 mutations occur more frequently
if the major D310 variants in matched blood lymphocytes194 The Journal of Thoracic and Cardiovascular Surgare non–C-7 variants and heteroplasmic.10,23 Generally,
the incidence of D310 mutations in cancers in the Caucasian
population is approximately 20%, with the highest in gastric
cancer (62.5%) and lowest in prostate and ovarian can-
cers.10 For patients with ESCC, the incidence of D310 mu-
tation was approximately 30%.12,13 However, the incidence
of D310 mutation was higher (77.8%) in our series. D310
polymorphisms (C-7 vs non–C-7) among different popula-
tions may explain this disparity. C-7 (wild type) is the
most common variant in Caucasian populations, whereas
most patients with ESCC in Taiwan (43/72, 59.7%) har-
bored major D310 variants other than C-7 in the noncancer-
ous esophageal mucosa. As mentioned above, non–C-7
variants are a risk factor for somatic D310 mutation, and pa-
tients with ESCC would be prone to somatic D310 mutation
when the corresponding noncancerous esophageal mucosa
harbors D310 variants other than C-7, which might explain
the high mutation rate in Taiwanese patients with ESCC.
Another possible explanation is that the samples we studied
were obtained from laser microdissection and free from con-
tamination with different cell types, and thus of higher ho-
mogeneity. We believe that the power to differentiate
D310 mutations is higher when tissues are obtained from mi-
crodissection.
It is noteworthy that a heteroplasmic to homoplasmic
shift of D310 variants and an increase in mtDNA copy num-
ber were observed in the progression from noncancerous
esophageal mucosa to cancerous ESCC nests and then to
metastatic lymph nodes (Table 2). This can be explained
by Nowell’s24 hypothesis of cancer evolution, which states
that most cancers arise from heterogeneous precancerous
lesions (with heteroplasmic D310 pattern), in which specific
clones acquire a proliferation advantage (increase of copy
number), followed by subsequent expansion of these clones
(with homoplasmic D310 pattern). To confirm the notion,
we further evaluated the associations of D310 patterns,
mtDNA copy number, and D310 clonal relationship be-
tween the noncancerous esophageal mucosa and the paired
cancerous ESCC nests among 56 patients with ESCC
harboring D310 mutations (Table 3). We found that 23
(41.1%) of the 56 patients exhibited a type IV heteroplas-
mic to homoplasmic D310 alteration (ie, to a single clone)
and had a higher mtDNA copy ratio (ie, increased clonal
quantity) (Table 3, P ¼ .048). Fifty-one (91.1%) of the
56 cancerous nests had D310 clonal relationship with their
noncancerous esophageal mucosa, including 36 (64.3%)
fully related and 15 (26.8%) partially related. Moreover,
36 (64.3%) of the 56 patients who had mutant D310 vari-
ants in the cancerous ESCC nests fully related to their non-
cancerous esophageal mucosa had a higher mtDNA copy
ratio than did those patients with a partially related relation-
ship (Table 4, P ¼ .047). On the basis of these findings, we
propose a model of clonal expansion during ESCC
progression from the viewpoint of mtDNA transmissionery c January 2010
FIGURE 1. A, Comparison of survival between patients with ESCC with and without somatic D310 mutations of mtDNA. Patients without D310 mutations
(n¼ 16) had better survival probability and lower hazard ratio than those with D310 mutations (n ¼ 56). B, Comparison of the survival between patients with
ESCC according to the degree of heteroplasmic D310 variation in noncancerous esophageal mucosa. Patients with lower degree heteroplasmy of mtDNA (n¼
43) had better survival probability and lower hazard ratio than those with higher degree heteroplasmy of mtDNA (n ¼ 29). C, Proposed model for the role of
mtDNA alterations in ESCC is illustrated. During the aging process with accumulative damages, heteroplasmic mtDNA variants may coexist in the patho-
logically normal esophageal mucosa, and the quantity of total mtDNA may increase to compensate for the defects in mtDNA. When carcinogenesis is initiated
or cancer is progressed, specific mtDNA variants harbored by the original malignant clone(s) are amplified during the process of clonal expansion.HR,Hazard
ratio; ROS, reactive oxygen species; ESCC, esophageal squamous cell carcinoma; mtDNA, mitochondrial DNA.
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ing (P ¼ .014) and alcohol consumption (P ¼ .005) were
highly associated with the increase in the mtDNA copy
number (Table 4).
Generally, the mtDNA molecules in an individual are
assumed identical at birth, and the characteristics of D310
variants in normal esophageal muscles and paired noncan-
cerous esophageal mucosa are supposed to be identical
and concordant.4 However, the percentage of homoplasmic
D310 variants in esophageal muscle tissue (43/72, 59.7%)The Journal of Thoracic and Cawas higher than that of the paired noncancerous esophageal
mucosa (26/72, 36.1%) (P ¼ .005), and esophageal mucosa
had more D310 variants than did the corresponding esopha-
geal muscle (2.2 vs 1.5, P¼ .002, Table 2). This discordance
may be explained by a model of accumulated damages in
mtDNA during the aging process,4,5 because mucosa is the
barrier of the underlying muscles (Figure 1, C, left). This in-
dicates that the pathologically normal esophageal mucosa
may be molecularly abnormal because of accumulated dam-
age at the DNA level.rdiovascular Surgery c Volume 139, Number 1 195
TABLE 4. Factors related to the D310 mutation and mtDNA copy
ratios in patients with esophageal squamous cell carcinoma
D310 mutation
mtDNA
DNA copy ratioz
Clinical
parameters
Yes
(n ¼ 56)
No
(n ¼ 16)
P
value
Mean
± SD
P
value
Age (y) (mean  SD) 62.1 
12.1
53.3 
13.4
.015* ND
Gender
Male (n ¼ 62) 48 14 .855y 1.28  0.70 .012*
Female (n ¼ 10) 8 2 0.97  0.24
Cigarette smoking
Yes (n ¼ 56) 43 13 .705y 1.33  0.71 .014*
No (n ¼ 16) 13 3 0.90  0.24
Alcohol drinking
Yes (n ¼ 51) 42 15 .164y 1.31  0.71 .005*
No (n ¼ 21) 14 1 0.96  0.29
D310 variants in
noncancerous
esophageal mucosa
No. of variants
(mean  SD)
2.5  1.0 1.0 <.001* ND
Distribution pattern
Heteroplasmy
(n ¼ 46)
46 0 <.001y 1.35  0.76 .015*
Homoplasmy
(n ¼ 26)
10 16 1.02  0.38
Major D310 variant
C-7 (n ¼ 29) 13 16 <.001y 1.03  0.39 .014*
Non-C-7 (n ¼ 43) 43 0 1.37  0.77
Cancer stage
T-status
T1 (n ¼ 7) 6 1 .388y 1.37  0.93 .382z
T2 (n ¼ 13) 10 3 1.32  0.80
T3 (n ¼ 29) 24 5 1.06  0.47
T4 (n ¼ 23) 16 7 1.36  0.70
N-status
N () (n ¼ 28) 22 6 .897y 1.20  0.65 .745*
N (þ) (n ¼ 44) 34 10 1.25  0.68
M-status
M0 (n ¼ 45) 36 9 .564y 1.34  0.71 .158z
M1a (n ¼ 12) 9 3 1.18  0.71
M1b (n ¼ 15) 11 4 0.97  0.32
Cancer stage (AJCC)
I (n ¼ 6) 5 1 .346y 1.11  0.71 .271z
II (n ¼ 21) 18 3 1.34  0.73
III (n ¼ 18) 13 5 1.42  0.73
IV (n ¼ 27) 20 7 1.06  0.53
AJCC, American Joint Committee on Cancer; SD, standard deviation; ND, not deter-
mined. *t test/Mann–Whitney test. yChi-square test. zANOVA/Kruskall–Wallis.
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heteroplasmic D310 variants of mtDNA in pathologically
normal esophageal mucosa may be a result of accumulated
damage, (2) D310 mutations of mtDNA in cancerous nests
are highly associated with the prognosis of patients with
ESCC, (3) the change from heteroplasmic to homoplasmic
D310 variants and an increase in mtDNA copy number196 The Journal of Thoracic and Cardiovascular Surgsuggest a clonal expansion during ESCC progression,
and (4) cigarette smoking and alcohol consumption are
highly associated with an increase in mtDNA copy
number.
Observation of multiple D310 variants in the noncancer-
ous esophageal mucosa led us to examine whether the de-
gree of heteroplasmy of the mtDNA in pathologically
normal mucosa affected the clinical outcome of ESCC. On
the basis of the mean and median number of D310 variants
in the noncancerous esophageal mucosa being 2.2 and 2.0,
respectively, we defined those who had less than 2 D310 var-
iants (n ¼ 43) as the low heteroplasmy group and those who
had more than 2 D310 variants (n ¼ 29) as the high hetero-
plasmy group. The results showed that high heteroplasmy
was associated with lower survival probability (P ¼ .005;
Figure 1, B). This suggests that unstable mtDNA with mul-
tiple variants (heteroplasmic mtDNA) in the noncancerous
esophageal mucosa is a poor prognostic factor for patients
with ESCC, even if the pathologic examination of their
mucosa looked ‘‘normal.’’
The mtDNA copy number has been shown to change in
many human cancers. An increase in the mtDNA copy num-
ber was reported in head and neck cancers14 and ESCC as
shown in this study. A decrease in mtDNA copy number
was noted in advanced hepatocellular carcinoma, gastric
cancer, breast cancers, and advanced lung cancers with
drug-resistance after neoadjuvant chemotherapy.11,15-17,21
On the basis of the mechanism of clonal expansion, the in-
crease in mtDNA copy number might be a compensation
for the damaged mtDNA to maintain mitochondrial func-
tion.14 When cancer progresses to advanced stages because
of excess damage, decompensation may be followed with
a decrease in mtDNA copy number, which results in im-
paired mitochondrial function and the Warburg effect.25
The roles of mtDNA copy number alterations in human can-
cers warrant further study.CONCLUSIONS
We have demonstrated that mtDNA alterations are associ-
ated with the progression and prognosis of ESCC. The so-
matic D310 mutations, which indicate mtDNA instability,
may play a role in the pathophysiology of ESCC. Whether
such mtDNA alterations affect the bioenergetic function of
mitochondria in affected tissues of patients with ESCC
requires further investigation.
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FIGURE E1. Laser microdissection (LMD) adopted for the harvest of samples from noncancerous esophageal mucosa, cancerous ESCC tissues, metastatic
lymph nodes, and esophageal muscular tissues of patients with ESCC. First panel: Noncancerous esophageal mucosa before (left) and after (right) LMD.
Second panel: Cancerous ESCC tissues before (left) and after (right) LMD. Third panel: Metastatic lymph nodes before (left) and after (right) LMD. Fourth
panel: Esophageal muscle tissues before (left) and after (right) LMD. ESCC, Esophageal squamous cell carcinoma.
197.e1 The Journal of Thoracic and Cardiovascular Surgery c January 2010
Evolving Technology/Basic Science Lin et al
E
T
/B
S
FIGURE E2. Types of somatic D310 alterations of mtDNA between noncancerous esophageal mucosa (left) and cancerous ESCC tissues (right). Arabic
number above the red arrow denotes the cytidine number before the indicated thymidine peak, which is shown in red color during D310 sequencing.
Type I, homoplasmic to homoplasmic (first row): The example shows homoplasmic C-7 variant to homoplasmic C-7 variant without D310 mutation.
Type II, homoplasmic to heteroplasmic (second row): The example shows homoplasmic C-7 variant to heteroplasmic C-8, C-7, C-9 variants with D310 mu-
tation. Type III, heteroplasmic to heteroplasmic (third row): The example shows heteroplasmic C-8, C-9, C10 variants to heteroplasmic C-9, C-8, C10 variants
with proportional change of the D310 variants with D310 mutation. Type IV, heteroplasmic to homoplasmic (fourth row): The example shows heteroplasmic
C-8, C-7 variants to homoplasmic C-8 variant with D310 mutation. Type V, homoplasmic to homoplasmic with variant shift (fifth row): The example shows
homoplasmic C-7 to homoplasmic C-8 with D310 mutation. ESCC, Esophageal squamous cell carcinoma.
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TABLE E1. Summary of the D310 variants between the paired noncancerous esophageal mucosa and the cancerous esophageal squamous cell
carcinoma nests in 72 patients with esophageal squamous cell carcinoma
Somatic
D310 mutation
Types of
D310 alteration Patient
Noncancerous esophageal mucosa Cancerous ESCC nests
D310*
variants Major Pattern
D310*
variants Major Pattern Relationship
No (n ¼ 16) I (homoplasmic
to homoplasmic)
A06 7 7 Homoplasmy 7 7 Homoplasmy Fully related
A10 7 7 Homoplasmy 7 7 Homoplasmy Fully related
A12 7 7 Homoplasmy 7 7 Homoplasmy Fully related
B03 7 7 Homoplasmy 7 7 Homoplasmy Fully related
B09 7 7 Homoplasmy 7 7 Homoplasmy Fully related
C08 7 7 Homoplasmy 7 7 Homoplasmy Fully related
C10 7 7 Homoplasmy 7 7 Homoplasmy Fully related
D02 7 7 Homoplasmy 7 7 Homoplasmy Fully related
D07 7 7 Homoplasmy 7 7 Homoplasmy Fully related
D09 7 7 Homoplasmy 7 7 Homoplasmy Fully related
E06 7 7 Homoplasmy 7 7 Homoplasmy Fully related
E07 7 7 Homoplasmy 7 7 Homoplasmy Fully related
E10 7 7 Homoplasmy 7 7 Homoplasmy Fully related
F06 7 7 Homoplasmy 7 7 Homoplasmy Fully related
F07 7 7 Homoplasmy 7 7 Homoplasmy Fully related
F10 7 7 Homoplasmy 7 7 Homoplasmy Fully related
Yes (n ¼ 8) II (homoplasmic
to heteroplasmic)
A03 7 7 Homoplasmy 7, 8 7 Heteroplasmy Partially related
A07 7 7 Homoplasmy 7, 9 7 Heteroplasmy Partially related
B10 8 8 Homoplasmy 8, 9 8 Heteroplasmy Partially related
C06 7 7 Homoplasmy 7, 10 7 Heteroplasmy Partially related
E01 7 7 Homoplasmy 7, 9, 10, 11 7 Heteroplasmy Partially related
E02 7 7 Homoplasmy 7, 8, 6 7 Heteroplasmy Partially related
F11 7 7 Homoplasmy 8, 7, 9 8 Heteroplasmy Partially related
G03 8 8 Homoplasmy 7, 8 7 Heteroplasmy Partially related
Yes (n ¼ 23) III (heteroplasmic
to heteroplasmic)
A01 8, 9, 10 8 Heteroplasmy 9, 8, 10 9 Heteroplasmy Fully related
A02 10, 9, 11, 8 10 Heteroplasmy 9, 10, 8, 11 9 Heteroplasmy Fully related
A04 9, 8, 10, 11 9 Heteroplasmy 9, 10, 8, 11 9 Heteroplasmy Fully related
B01 8, 9 8 Heteroplasmy 8, 9 8 Heteroplasmy Fully related
B04 8, 9 8 Heteroplasmy 8, 7, 6 8 Heteroplasmy Partially related
B06 8, 9, 10, 11 8 Heteroplasmy 8, 9, 10 8 Heteroplasmy Fully related
B08 9, 8, 10 9 Heteroplasmy 7, 8 7 Heteroplasmy Partially related
B12 7, 9, 8 7 Heteroplasmy 9, 7, 8 9 Heteroplasmy Fully related
C02 7, 8 7 Heteroplasmy 10, 9, 8 10 Heteroplasmy Partially related
C04 8, 7, 9, 10 8 Heteroplasmy 9, 8, 7, 10 9 Heteroplasmy Fully related
C09 9, 8, 7 9 Heteroplasmy 10, 9 10 Heteroplasmy Partially related
C11 8, 9 8 Heteroplasmy 8, 9 8 Heteroplasmy Fully related
D05 8, 9 8 Heteroplasmy 8, 7, 6 8 Heteroplasmy Partially related
D06 9, 8 9 Heteroplasmy 9, 8 9 Heteroplasmy Fully related
D08 11, 10, 9 11 Heteroplasmy 9, 8 9 Heteroplasmy Partially related
E04 9, 7, 10, 8 9 Heteroplasmy 8, 9, 10 8 Heteroplasmy Fully related
E05 8, 9, 7 8 Heteroplasmy 8, 9, 7 8 Heteroplasmy Fully related
E09 9, 8 9 Heteroplasmy 9, 8 9 Heteroplasmy Fully related
F02 8, 7, 9 8 Heteroplasmy 8, 9 8 Heteroplasmy Fully related
F03 8, 9, 10 8 Heteroplasmy 8, 9 8 Heteroplasmy Fully related
F05 9, 10, 8 9 Heteroplasmy 8, 9 8 Heteroplasmy Fully related
F08 8, 9, 10, 7 8 Heteroplasmy 9, 10, 8, 7 9 Heteroplasmy Fully related
G02 7, 8 7 Heteroplasmy 7, 9 7 Heteroplasmy Partially related
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TABLE E1. Continued
Somatic
D310 mutation
Types of
D310 alteration Patient
Noncancerous esophageal mucosa Cancerous ESCC nests
D310*
variants Major Pattern
D310*
variants Major Pattern Relationship
Yes (n ¼ 23) IV (heteroplasmic
to homoplasmic)
A05 8, 7, 9 8 Heteroplasmy 8 8 Homoplasmy Fully related
A08 8, 9, 10 8 Heteroplasmy 8 8 Homoplasmy Fully related
A09 8, 9, 10 8 Heteroplasmy 8 8 Homoplasmy Fully related
A11 10, 9 10 Heteroplasmy 8 8 Homoplasmy Not related
B02 9, 8, 10 9 Heteroplasmy 8 8 Homoplasmy Fully related
B05 8, 7, 9, 10 8 Heteroplasmy 8 8 Homoplasmy Fully related
B07 8, 9, 7 8 Heteroplasmy 8 8 Homoplasmy Fully related
B11 8, 10, 9 8 Heteroplasmy 8 8 Homoplasmy Fully related
C01 8, 9, 10 8 Heteroplasmy 8 8 Homoplasmy Fully related
C03 7, 8 7 Heteroplasmy 8 8 Homoplasmy Fully related
C05 8, 9 8 Heteroplasmy 8 8 Homoplasmy Fully related
C07 9, 8, 10 9 Heteroplasmy 8 8 Homoplasmy Fully related
C12 8, 9, 10 8 Heteroplasmy 8 8 Homoplasmy Fully related
D01 8, 9, 7 8 Heteroplasmy 7 7 Homoplasmy Fully related
D03 9, 8 9 Heteroplasmy 8 8 Homoplasmy Fully related
D04 8, 10,9 8 Heteroplasmy 8 8 Homoplasmy Fully related
D10 8, 7 8 Heteroplasmy 8 8 Homoplasmy Fully related
D12 8, 9 8 Heteroplasmy 8 8 Homoplasmy Fully related
E08 7, 8 7 Heteroplasmy 7 7 Homoplasmy Fully related
E11 10, 9 10 Heteroplasmy 7 7 Homoplasmy Not related
F04 9, 8, 10, 11 9 Heteroplasmy 4 4 Homoplasmy Not related
F09 8, 7 8 Heteroplasmy 8 8 Homoplasmy Fully related
G04 8, 9, 7 8 Heteroplasmy 8 8 Homoplasmy Fully related
Yes (n ¼ 2) V (A homoplasmic
to B homoplasmic)
E12 7 7 Homoplasmy 8 8 Homoplasmy Not related
G01 7 7 Homoplasmy 8 8 Homoplasmy Not related
*The cytidine numbers of D310 variants are listed in order according to the detected sequencing peaks.
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